Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reviewed early research on topical finasteride for androgenetic alopecia, finding it appears safe and promising, though further investigation is needed to determine optimal dosing, frequency, and potential applications for other types of alopecia.

In this study, 32% of men continued taking finasteride for androgenetic alopecia after 1 to 3 years, but only a small percentage reported hair growth.

This study found that 32% of men continued finasteride use for 1 to 3 years, with many reporting poor hair growth results.

Combining platelet-rich plasma with 5% minoxidil solution improves hair regrowth in androgenetic alopecia patients.

This study found that sexual side effects occurred in a small percentage of patients using combined finasteride and minoxidil, but these were not common reasons for discontinuing treatment.

This study found that finasteride delivered through a nano-transferosomal gel showed improved penetration through skin layers compared to a conventional gel, suggesting a potential alternative for oral administration.

In this study, dermatologists from the Spanish Hair and Nail Disorders Group viewed post-finasteride syndrome as rare and primarily of psychiatric origin, with limited scientific evidence supporting its existence.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

The abstract reports no new clinical results; it describes finasteride’s mechanism of action in androgenetic alopecia and mentions unpublished trial results by the manufacturer and investigators.

Finasteride significantly increases scalp hair and prevents hair loss in young and middle-aged men.

This review discusses current medical therapies available for treating hair loss and emphasizes the importance of understanding these options, but it presents no new results.

PRP treatment for hair loss shows promise, with 58% of patients satisfied and most noticing improvement within 6 months.

This study found that some cancer cells exhibit neuronal-like characteristics, which may serve as a mechanism of resistance.

This review discusses the advancements in understanding and treating androgenetic alopecia and alopecia areata but reports no clinical findings; the authors emphasize the need for further research on molecular control mechanisms.

This chapter reviews the causes, prevalence, and prognosis of androgenetic alopecia and discusses treatments like topical minoxidil and systemic finasteride to stop hair loss and potentially increase hair density.

This review discusses the sexual side effects of long-term finasteride usage in men, noting varied reports of sexual dysfunction which typically improve over time; it presents no new experimental data.

Finasteride improves hair growth and satisfaction in men with male pattern baldness but may cause sexual side effects.

This study concluded that finasteride, cyproterone acetate, and flutamide were similarly effective at reducing hirsutism in women, though they acted through different mechanisms.

This study developed a sensitive HPLC-MS/MS method for determining cyproterone acetate levels in human plasma and found no significant difference in its concentration between two oral formulations in bioequivalence testing.

A new protein linked to Alzheimer's was discovered, and a hair loss treatment showed effectiveness but had some sexual side effects.

This review discusses recent advances in hair follicle research, highlighting therapeutic and cosmetic applications, but reports no new study results.

In this study, 1 mg/day finasteride lowered serum PSA concentration in men aged 40–60, suggesting that PSA adjustment recommendations for prostate cancer screening using 5 mg/day finasteride should also apply to this lower dose for hair loss treatment.

In this study of men with androgenetic alopecia, daily finasteride 1 mg alongside hair transplant improved scalp hair density and growth of nontransplanted hair compared to placebo over 48 weeks.

This study found that finasteride 1 mg daily, taken before and after hair transplant surgery, significantly improved scalp hair coverage and density in men with androgenetic alopecia compared to placebo.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

The study found that finasteride increased endoplasmic reticulum stress and reduced fertility in rats, effects that were alleviated by the administration of DA-9401.

This study concluded that finasteride 1 mg does not significantly affect the metabolism of omeprazole in young healthy Japanese male extensive or poor metabolizers for CYP2C19.

MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.

This study found that global online interest in finasteride and its sexual side effects significantly increased after the FDA issued safety warnings in 2011.

This study found that finasteride reduced sperm count, motility, and levels of reproductive hormones, indicating negative effects on fertility in albino male rats.